Market Access

Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes that impact Medicare, as well as the Foundation's near-term goals.

Biopharma companies can foster patient-centered innovation by focusing on unmet needs along each stage of the patient journey while collaborating with key stakeholders directly or indirectly responsible for disease management.

Rohit Gupta, vice president of analytics strategy and transformation at Beghou Consulting, addresses the controversial middlemen of the drug pricing world, the pharmacy benefit managers (PBMs). Can increased competition and other innovative solutions loosen their grip and prevent further consolidation?

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT

Webinar Date/Time: Tuesday, February 28, 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET

As pharmaceutical market access teams head into 2023, these ten trends detail why evolved preparation, thought, and engagement will be needed to meet post-pandemic marketplace expectations.

As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.

Supporting health plan clinical preparation and financial modeling.

Using market access data from day one of your drug development and commercialization journey puts your brand in the best position to succeed at launch.

Emerging biopharma companies are critical to the vibrancy of the healthcare landscape, but their long road of drug development fails to translate to successful market launch more often than it does for large pharma. What can be done to improve those odds?

Webinar Date/Time: Tuesday, Dec 6, 2022, 11am PT | 2pm ET

Webinar Date/Time: Wednesday, November 30, 2022, 1 pm EDT

Life sciences professionals will need to keep up with market demand for biologics and biosimilars.

Commercial Health Insurance may bring more opportunities for market access in China.

Different paths to formulary decision-making.

FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.

A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Gaps remain in the pre-approval information process leave payers without all of the information they need to make the proper decisions.

The BCG Market Access Roundtable outlines the new and advanced access competencies required to enable functional operationalization and delivery of this critical role in biopharma—today a key strategic partner in achieving overall business goals.

Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

Using data visualizations to improve access to payers.

New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.

Reversing non-formulary status will usually require new data.